Proteflazid®: clinical and economic substantiation for use in therapy of herpes infection
DOI:
https://doi.org/10.24959/cphj.16.1396Keywords:
herpes infections, antiviral drugs, acyclic nucleosides, Proteflazid®, clinical efficiency, cost of treatmentAbstract
Epidemiological data indicate the widespread dissemination and constant dynamics of the incidence rate of herpesvirus infections due to a variety of forms and transmission paths of the virus, highly contagious and life-long persistence of the herpes virus in the body of the infected persons and the lack of effectiveness of existing treatments. Acyclic guanosine derivatives are the main group of antiviral drugs traditionally used for the causal treatment of herpes infections. They have a number of disadvantages, in particular formation of the virus resistance in a long-term use, the need to involve immunotherapy, as well as the high cost of treatment. The accumulated clinical experience with the original Ukrainian drug Proteflazid® (drops) in treating viral infections, including HHV- infections, shows its high clinical efficacy and safety. A relative estimation of the course treatment costs of herpes-induced infections using antiviral drugs has demonstrated the economic expediency of Proteflazid® with the purpose of treatment and maintenance therapy. Proteflazid® takes the medium sized niche among other antiherpetic drugs. In addition, due to the multi-vector nature of its pharmacodynamic effects (direct antiviral, immunomodulating, interferon-stimulating, antioxidant, apoptosis-modulating, etc.) Proteflazid® allows to exclude antioxidants, immunomodulators from the antiherpetic therapy scheme, or to adjust their use, and it can significantly reduce the cost per a course of treatment.References
Дубоссарская З.М., Дубоссарская Ю.А. // Медицинские аспекты здоровья женщины. – 2007. – №5 (8). – С. 38-40.
Исаков В.А., 2. Архипова Е.И., Исаков В.Д. Герпесвирусные инфекции человека. – С.Пб.: СпецЛит, 2013. – 670 с.
Исаков В.А., 3. Рыбалкин С.Б., Романцов М.Г. Герпесвирусная инфекция: Рекоменд. для врачей. – С.Пб., 2006. – 96 с. 4. Казмирчук В.Е.,
Мальцев Д.В. // Укр. мед. часопис. – 2012. – №5 (91). – IX/X [Електронний ресурс] – Режим доступу до сайту: http://www.umj.com.ua/article/42561/rekomendacii-po-lecheniyugerpesvirusnyx-infekcij-cheloveka/ CLINICAL PHARMACY. – 2016. – Vol. 20, No. 3 11ISSN 1562-725X
Камінський В.В., Шалько М.Н., Гриневич О.Й. // Здоровье женщины. – 2014. – №6 (92). – С. 160-164.
Компендиум. Лекарственные препараты 2016 [Електронний ресурс] – Режим доступу до сайту: http:// соmpendium.com.ua / prices/
Коровина А.Н., Куханова М.К., Кочетков С.Н. // BiotechnologiaActa. – 2013. – Vol. 6, №4. – С. 78-85.
Кускова Т.К., Белова Е.Г. // Лечащий врач. – 2004. – №5/4 [Електронний ресурс] – Режим доступу до сайту: http://www.lvrach.ru/2004/05/
Кэри Ч., Ли Х., Велтье К. Терапевтический справочник Вашингтонского университета / Пер. с англ. под ред. Д.В.Самойлова и М.А.Осипова. – 2-е рус. изд. – М.: «Практика», 2000. – 879 с.
Никулин Л.А., Александрова О.К., Сивак В.В., Боровикова Е.В. Герпетическая инфекция (Herpessimplex) [Електронний ресурс] – Режим доступу до сайту: http://www.infectology.ru/ruk/herpes/index.aspx/
Редькин Ю.В., Одокиенко А.Ю. // Вестник дерматологии и венерологии. – 2006 – №3 [Електронний ресурс] – Режим доступу до сайту: http://www.mediasphera.ru/journals/vestnik/detail/125/1517/
Современная терапия герпесвирусных инфекций: Руководство для врачей / В.А.Исаков, С.А.Сельков, Л.К.Мошетова, Г.М.Чернакова. – СПб.: М., 2004. – 168 с.
Шестакова И.В., Ющук Н.Д. // Лечащий врач. – 2001. – №2 [Електронний ресурс] – Режим доступу до сайту: http://www.lvrach.ru/2011/02/15435133/
Acosta E.P., Fletcher C.V. // The Annals of Pharmacotherapy. – 1997. – Vol. 31, №2. – Р. 185-191.
Akalin E., Sehgal V., Ames S. et al. // Am. J. of Transplantation. – 2003. – Vol. 3, №6. – Р. 731-735.
Beeson W.H., Rachel J.D. // Dermatologic Surgery. – 2002. – Vol. 28, №4. – Р. 331-336.
Blein C., Gavazzi G., Paccalin M. et al. // BMC Infect Dis. – 2015. – Vol. 19, №15. – Р. 350.
Brady R.C., Bernstein D.I. // Antiviral Res. – 2004. – Vol. 61, №2. – P. 73-81.
Bricout H., Haugh M., Olatunde O., Prieto R.G. // BMC Public Health. – 2015. – Vol. 15. – Р. 466-480.
Chrisp P., Clissold S.P. // Retinitis Drugs. – 1991. – Vol. 41, №1. – Р. 104-129.
Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications / M.J.Korndewal, L.Mollema, I.Tcherniaeva, F. van der Klis // J. Clin. Virol. – 2015. – Vol. 63. – Р. 53-58.
De Clercq E. // J. of Clinical Virol. – 2004. – Vol. 30, №2. – P. 115-133.
De S.K., Hart J.C., Breuer J. // Curr Opin Infect Dis. – 2015. – Vol. 28, №6. – Р. 589-595.
Drug Bankdatabase, Drug Bank Version: 3.0 [Електронний ресурс] – Режим доступу до сайту: http://www.drugbank.ca/
Duncan S.R., Grgurich W.F., Iacono A.T. et al. // Am. J. of Respiratory and Critical Care Medicine. – 1994. – Vol. 150, №1. – Р. 146-152.
Faulds D., Heel R. // Drugs. – 1990. – Vol. 39, №4. – Р. 597-638.
Johnson R.W., Alvarez-Pasquin M.-J., Bijl M. // Ther. Adv. Vaccines. – 2015. – Vol. 3 (4). – Р. 109-120.
Kaminsky V.V., Litus O.I., Grynevych O.I. et al. // Sci. and Education Studies. – 2015. – Vol. 3, №2 (16). – P. 705-727.
Nilsson J., Cassel T., Lindquist L. // BMC Infect Dis. – 2015. – Vol. 15. – Р. 215-222.
Pinchinat S., Cebrian-Cuenca A., Bricout H., Johnson R. // BMC. Infect. Dis. – 2013. – Vol. 13. – P. 170-183.
Tan B.H. // Curr. Treat. Options. Infect. Dis. – 2014. – Vol. 6 (3). – Р. 256-270.
White P.J., Garnett G.P. // Sex Transm Infect. – 1999. – Vol. 75 (1). – Р. 49-54.
Yawn B., Gilden D. // Neurol. – 2013. – Vol. 81. – Р. 928-930.
Whitley R.J., Kimberlin D.W., Roizman B. // Diseases. – 1998. – Vol. 26. – Р. 541-555.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).